These efficacy variables appeared greater at higher doses , although there are no significant differences between 10 and 20 mg dose .
Specific adverse events with vardenafil  included flushing , dyspepsia , headache , and rhinitis .
Vardenafil was not significantly associated with serious cardiovascular events or death .
Vardenafil , in all treatment regimens , shows to possess superior efficacy to placebo in the treatment of patients with erectile dysfunction .
Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups.
OBJECTIVES To assess whether vardenafil would improve  erectile function  irrespective of etiology , baseline severity , or patient age . The consistency of the response over time was also evaluated . METHODS A multicenter , r and omized , double-blind , placebo-controlled at-home study of vardenafil treatment ( 5 , 10 , and 20 mg ) was performed . This secondary analysis compared the mean International Index of Erectile Function ( IIEF ) erectile function domain scores of various subgroups at 12 weeks of treatment . These population s included organic , psychogenic , or mixed etiologies ; mild , moderate , or severe baseline severity ; and four age groups ( younger than 45 , 45 to 55 , 56 to 65 , and older than 65 years ) . In addition , all IIEF domains were compared at sequential 4-week periods , before and during treatment . RESULTS In the 580 men of the intent-to-treat population , the mean erectile function domain scores were statistically greater than placebo , irrespective of etiology , baseline severity , or age . This was seen at all dosages . Compared with placebo , vardenafil statistically improved the IIEF domain scores of erectile function , orgasmic function , intercourse satisfaction , and overall satisfaction after 4 weeks of treatment , and these improvements were maintained for 12 weeks . The rates of the most common adverse events ( headache , flushing , and dyspepsia ) were either constant or declined over time ; they were generally mild to moderate and transient in nature . CONCLUSIONS Vardenafil improved  erectile function  regardless of the general etiology , baseline severity of erectile dysfunction , or patient age . Improvements in erectile function and other key IIEF domains were consistently seen throughout the study
These efficacy variables appeared greater at higher doses , although there are no significant differences between 10 and 20 mg dose .
Specific adverse events with vardenafil  included flushing , dyspepsia , headache , and rhinitis .
Vardenafil was not significantly associated with serious cardiovascular events or death .
Vardenafil , in all treatment regimens , shows to possess superior efficacy to placebo in the treatment of patients with erectile dysfunction .